News

COVID FAQ – Preventative medication and antiviral treatments

20 September 2022

MS Plus has put together a brief Q&A to help you navigate the latest information and advice on COVID preventative medication and antivirals.

MS Plus Executive Manager Client Engagement and Wellbeing Jodi Haartsen is once again joined by Neurologist and Associate Professor Anneke Van Der Walt and Clinical Nurse Consultant Louise Rath from The Alfred.

Please note: this video discusses a preventative medication and antiviral treatments for COVID. However, you may not require treatment – please seek advice from your healthcare team.

 

 

Related News

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

MS News

PBS access to two vital MS treatments under threat as Government decision looms

1 July 2026

Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of government-driven policy-related price reductions.

Read More
XX chromosomesSimon's story

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

COVID FAQ – Preventative medication and antiviral treatments